Services are coordinated by the CIS Co-Directors, Drs. Becich and Chandran. and are described in the text that follows. The CIS facilitates quality controlled collection of clinical information via a variety of information systems managed by Dr. Becich and his team. These clinical information systems which feed data to the research information systems ofthe CIS include the Clinical Trials Management Application (CTMA), the Pathology Laboratory Systems (Corner's CoPath Plus for anatomic pathology and Misys'Flexilab for clinical pathology), the Immunologic Monitoring and Cellular Products Laboratories (IMCPL), the Registry Research Information Service (ImPath), and three electronic medical records systems [the Medical Archival System (MARS, Inc.), Corner's PowerChart and Epic's EpicCare System]. These seven clinical systems (with the exception of ImPath) all use HL7 (Health Level 7, see www.hl7.org/) messaging to pass data to (and in some instances from) our research information systems. The diagram below shows the information flow from our clinical systems to our honest brokers information systems (Cancer Registry &Tissue Banking Systems). The research data that is in highest demand in our current environment comes from four sources: 1) clinical trials, 2) clinical annotation of tissue and serum samples, 3) information management and analysis related to microarray (tissue and cDNA) and proteomic experiments, and 4) clinical abstracts of patient treatment and outcome for translational research. We have built CTMA to serve the complete needs of clinical trials at UPCI. This is a system that manages a clinical trial from protocol proposal to closing of the trial. The functional modules of CTMA are described in the sections that follow. Data from the anatomic pathology Laboratory Information Systems or LIS (CoPath Plus) is entered into Synoptic Templates (structured data entry forms) that were developed by the Pathology Department in collaboration with the surgeons, medical oncologists, and other key UPCI members. These cancer checklists are entered into pathology reports and stored in discrete data elements in the LIS. These data are then stored in our data warehouse and combined with data extracted from the ImPath Cancer Registry. The integrated Cancer Registry has a research information services group that focuses on collecting organ site specific data into the ImPath system from a variety of sources, including our two medical record systems, our Radiology Information Systems, our Radiation Therapy Information System, and chart review in medical oncologists'and surgeons'offices. The Registry Research Information Service (RIS) and the LIS units form the foundation of our Tissue Banking and Pathology Tools. Our tissue banking and pathology tools include the caBIG? program's caTIES and caTISSUE Suite and other systems that were developed for cancer researchers to gain access to de-identified clinical, pathology, and outcomes data to identify cohorts for study. The Oracle data warehouse that is the basis for all of our research applications can also be queried via Discovery Tools (Oracle) to do ad hoc queries to structure data in SPSS and other SQL transforms for use by biostatisticians, cancer researchers, and clinical outcomes researchers. We have a sophisticated set of output tools developed in Crystal Reports (Crystal Decisions;Vancouver, BC) to provide detailed reporting formats. We work collaboratively with the Clinical Research Services and the Biostatistics Facility to provide them with high quality reports and data output to facilitate cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-25
Application #
8519330
Study Section
Special Emphasis Panel (ZCA1-RTRB-L)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
25
Fiscal Year
2013
Total Cost
$310,020
Indirect Cost
$69,739
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Vyas, Avani R; Moura, Michelle B; Hahm, Eun-Ryeong et al. (2016) Sulforaphane Inhibits c-Myc-Mediated Prostate Cancer Stem-Like Traits. J Cell Biochem 117:2482-95
Pollack, Ian F; Jakacki, Regina I; Butterfield, Lisa H et al. (2016) Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study. J Neurooncol :
Concha-Benavente, Fernando; Srivastava, Raghvendra M; Trivedi, Sumita et al. (2016) Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer. Cancer Res 76:1031-43
Posluszny, Donna M; Dew, Mary Amanda; Beckjord, Ellen et al. (2016) Existential challenges experienced by lymphoma survivors: Results from the 2010 LIVESTRONG Survey. J Health Psychol 21:2357-66
Delgado, Evan; Boisen, Michelle M; Laskey, Robin et al. (2016) High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcome. Gynecol Oncol 141:348-56
Kirkwood, Caitlin M; MacDonald, Matthew L; Schempf, Tadhg A et al. (2016) Altered Levels of Visinin-Like Protein 1 Correspond to Regional Neuronal Loss in Alzheimer Disease and Frontotemporal Lobar Degeneration. J Neuropathol Exp Neurol 75:175-82
Chen, Mingqing; Sun, Fan; Han, Lei et al. (2016) Kaposi's sarcoma herpesvirus (KSHV) microRNA K12-1 functions as an oncogene by activating NF-κB/IL-6/STAT3 signaling. Oncotarget 7:33363-73
Gojo, Ivana; Beumer, Jan H; Pratz, Keith W et al. (2016) A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia. Clin Cancer Res :
Blundon, Malachi A; Schlesinger, Danielle R; Parthasarathy, Amritha et al. (2016) Proteomic analysis reveals APC-dependent post-translational modifications and identifies a novel regulator of β-catenin. Development 143:2629-40
Rodler, Eve T; Kurland, Brenda F; Griffin, Melissa et al. (2016) Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer. Clin Cancer Res 22:2855-64

Showing the most recent 10 out of 885 publications